HCV Helicase Inhibitors and Methods of Use Thereof
申请人:Aube Jeffrey
公开号:US20140227225A1
公开(公告)日:2014-08-14
The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.
Cu‐Catalyzed Coupling Reactions of Sulfonamides with (Hetero)Aryl Chlorides/Bromides
作者:Qiaoli Li、Lanting Xu、Dawei Ma
DOI:10.1002/anie.202210483
日期:2022.10.24
of (hetero)aryl halides proceeds with excellent reaction scope by using oxalamides or 4-hydroxypicolinamides as the ligands. For bromides, only 2–5 mol % CuI and oxalamides were required. For chlorides, increasing catalytic loadings to 10 mol % Cu2O and ligands was needed. Direct sulfonamidation of four chloro-containing marketed drugs and preparation of two sulfonamide drugs were achieved under these
通过使用草酰胺或 4-羟基吡啶甲酰胺作为配体,Cu 催化的(杂)芳基卤化物磺酰胺化反应具有出色的反应范围。对于溴化物,仅需要 2–5 mol% CuI 和草酰胺。对于氯化物,需要将催化负载增加到 10 mol% Cu 2 O 和配体。在此条件下实现了四种含氯市售药物的直接磺酰胺化和两种磺胺类药物的制备。